Despite the successful effect of anlotinib in certain advanced lung cancer cases with BM [68], cranial radiotherapy (CRT) is currently regarded as the standard treatment regimen for NSCLC patients without a specific gene mutation or EGFR/ALK/ROS1-TKI resistance. Here, ROS1 is linked to non-small cell lung carcinoma.